- Home
- DERM vs PBYI Comparison
DERM vs PBYI Comparison
Compare DERM & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DERM
- PBYI
- Stock Information
- Founded
- DERM 2014
- PBYI 2010
- Country
- DERM United States
- PBYI United States
- Employees
- DERM N/A
- PBYI N/A
- Industry
- DERM Biotechnology: Pharmaceutical Preparations
- PBYI Biotechnology: Pharmaceutical Preparations
- Sector
- DERM Health Care
- PBYI Health Care
- Exchange
- DERM Nasdaq
- PBYI Nasdaq
- Market Cap
- DERM 165.6M
- PBYI 171.7M
- IPO Year
- DERM 2021
- PBYI N/A
- Fundamental
- Price
- DERM $7.23
- PBYI $3.15
- Analyst Decision
- DERM Strong Buy
- PBYI Strong Buy
- Analyst Count
- DERM 2
- PBYI 1
- Target Price
- DERM $10.50
- PBYI $7.00
- AVG Volume (30 Days)
- DERM 108.1K
- PBYI 295.4K
- Earning Date
- DERM 08-12-2025
- PBYI 08-07-2025
- Dividend Yield
- DERM N/A
- PBYI N/A
- EPS Growth
- DERM N/A
- PBYI 143.51
- EPS
- DERM N/A
- PBYI 0.77
- Revenue
- DERM $56,243,000.00
- PBYI $232,709,000.00
- Revenue This Year
- DERM $28.99
- PBYI N/A
- Revenue Next Year
- DERM $52.61
- PBYI N/A
- P/E Ratio
- DERM N/A
- PBYI $4.21
- Revenue Growth
- DERM N/A
- PBYI 2.68
- 52 Week Low
- DERM $3.54
- PBYI $2.23
- 52 Week High
- DERM $8.25
- PBYI $4.13
- Technical
- Relative Strength Index (RSI)
- DERM 49.52
- PBYI 42.22
- Support Level
- DERM $6.90
- PBYI $3.03
- Resistance Level
- DERM $8.09
- PBYI $3.25
- Average True Range (ATR)
- DERM 0.36
- PBYI 0.13
- MACD
- DERM -0.04
- PBYI -0.02
- Stochastic Oscillator
- DERM 27.78
- PBYI 30.77
About DERM Journey Medical Corporation
Journey Medical Corp is a commercial stage pharmaceutical company focused on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions. The company's current product portfolio includes eight FDA-approved prescription drugs for dermatological conditions that are marketed in the U.S. Some of the group's products are Qbrexza, Accutane, Amzeeq, Exelderm and others.
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis resulting into apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.